BioNTech and OncoC4 announced positive median overall survival results from their PRESERVE-003 Phase 3 trial for metastatic squamous non-small cell lung cancer. The investigational therapy, gotistobart, nearly doubled survival times compared to standard chemotherapy, leading to a stock jump for BioNTech.
BioNTech and OncoC4 released promising first median overall survival results from stage 1 of their global PRESERVE-003 Phase 3 trial for gotistobart (BNT316 or ONC-392). The data showed that the investigational therapy nearly doubled survival times (18.5 months vs. 10 months) compared to standard chemotherapy for a specific patient population with metastatic squamous non-small cell lung cancer. This positive clinical development is a significant catalyst for BioNTech, indicating potential for a new effective treatment in a challenging cancer type. The stock's immediate jump reflects short-term investor optimism, and successful completion of the ongoing pivotal stage 2 could lead to long-term revenue opportunities and market share gains in oncology. However, regulatory approval and market adoption remain future hurdles.